ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...
Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific ...
Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of ...
Chonnam National University has once again solidified its international reputation as Korea's leading institution in "nano-regenerative medicine" ...
The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...
Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation November 26, 2025 9:00 ...
Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...
MedPage Today on MSN
Dual targeting of GPRC5D and BCMA gets high response rate in extramedullary myeloma
O RLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback